Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Eton Pharmaceuticals Inc.

    NASDAQ: ETON · Real-Time Price · USD
    14.30
    -0.21 (-1.45%)
    At close: Jun 13, 2025, 3:59 PM
    14.48
    1.25%
    After-hours: Jun 13, 2025, 05:54 PM EDT
    -1.45%
    Bid 14.3
    Market Cap 383.49M
    Revenue (ttm) 48.33M
    Net Income (ttm) -4.58M
    EPS (ttm) -0.18
    PE Ratio (ttm) -79.44
    Forward PE 11.8
    Analyst Strong Buy
    Ask 14.48
    Volume 731,995
    Avg. Volume (20D) 319,330
    Open 14.55
    Previous Close 14.51
    Day's Range 14.14 - 14.80
    52-Week Range 3.18 - 21.48
    Beta 1.28

    About ETON

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ETON
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ETON stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 weeks ago
    -5.78%
    ETON stock has given up its prior gain. Eton Pharm... Unlock content with Pro Subscription
    2 weeks ago
    -5.78%
    Eton Pharmaceuticals shares are trading higher after the company announced it received FDA approval for its KHINDIVI oral solution. Additionally, HC Wainwright & Co. raised its price target on the stock from $33 to $35 and maintained a Buy rating.
    news image

    1 week ago · seekingalpha.com

    Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside

    Eton Pharmaceuticals is experiencing explosive rare-disease revenue growth, with a 117% YoY increase and a robust pipeline fueling future expansion. Despite a 400% share price surge, ETON remains attr...

    news image

    1 week ago · zacks.com

    Eton Pharmaceuticals (ETON) Upgraded to Buy: Here's Why

    Eton Pharmaceuticals (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    1 week ago · zacks.com

    Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why

    Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it...

    news image

    2 weeks ago · benzinga.com

    FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue

    The U.S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.'s ETON new drug application (NDA) for Khindivi (hydrocortisone) oral solution as a replacement therapy for pediatric pat...

    news image

    3 weeks ago · seekingalpha.com

    Eton Pharmaceuticals Set To Dominate Orphan Drug Niche

    Giant pharma companies are not the right owners of ultra-rare disease orphan drugs. The associated revenue streams are simply too small. ETON can acquire and develop these drugs, better serving patien...

    news image

    1 month ago · seekingalpha.com

    Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript

    Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer ...

    news image

    1 month ago · zacks.com

    Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates

    Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.03 per share a year ago.

    news image

    1 month ago · zacks.com

    Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

    Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    2 months ago · seekingalpha.com

    Eton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call Transcript

    Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q4 2024 Earnings Conference Call March 18, 2025 10:00 AM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Offic...

    news image

    2 months ago · zacks.com

    Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates

    Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago.

    Add to Watchlist